Table 2.
Correlation analysis of numerical variables (Spearman’s Rho)
| Parameter | Time point (day) | r | p | |
|---|---|---|---|---|
| Clinical | Immune system | |||
| Administered radiation activity (GBq) | Granulocyte count | 0 | 0.40 | 0.045 |
| 7 | 0.43 | 0.04 | ||
| 28 | 0.46 | 0.038 | ||
| Lymphocyte count | 7 | − 0.56 | 0.005 | |
| CD8 + T cells | 7 | − 0.52 | 0.011 | |
| B cells | 7 | − 0.51 | 0.013 | |
| 28 | − 0.63 | 0.002 | ||
| HLA-DR + T cells | 2 | − 0.42 | 0.042 | |
| 7 | − 0.45 | 0.03 | ||
| HLA-DR + B cells | 2 | − 0.46 | 0.023 | |
| 7 | − 0.54 | 0.008 | ||
| 28 | − 0.62 | 0.003 | ||
| CD45RA + T cells | 7 | − 0.57 | 0.005 | |
| CD8 + CD45RA + cells | 7 | − 0.63 | 0.001 | |
| 28 | − 0.44 | 0.049 | ||
| CD8 + CD45R0 + cells | 7 | − 0.50 | 0.016 | |
| PHA LTT | 2 | − 0.46 | 0.024 | |
| 7 | − 0.43 | 0.039 | ||
| LTT Cum. antigen score | 7 | − 0.64 | 0.001 | |
| PHA IFN-γ ELISpot | 2 | − 0.49 | 0.017 | |
| 7 | − 0.50 | 0.014 | ||
| ConA IFN-γ ELISpot | 2 | − 0.45 | 0.031 | |
| 7 | − 0.48 | 0.021 | ||
| PWM IFN-γ ELISpot | 2 | − 0.45 | 0.032 | |
| TET IFN-γ ELISpot | 7 | − 0.53 | 0.009 | |
| CAN IFN-γ ELISpot | 2 | − 0.45 | 0.03 | |
| Target volume dose (Gy) | B cells | 1 | − 0.52 | 0.009 |
| 7 | − 0.46 | 0.028 | ||
| HLA-DR + B cells | 1 | − 0.55 | 0.005 | |
| 2 | − 0.63 | 0.001 | ||
| 7 | − 0.52 | 0.01 | ||
| HSV-1 LTT | 7 | − 0.58 | 0.003 | |
| PHA IFN-γ ELISpot | 2 | − 0.44 | 0.037 | |
| Lung dose (Gy) | CD8 + T cells | 7 | − 0.44 | 0.039 |
| CD8 + CD45RA + cells | 7 | − 0.50 | 0.019 | |
| LTT Cum. Antigen score | 7 | − 0.46 | 0.03 | |
| TET IFN-γ ELISpot | 28 | − 0.54 | 0.018 | |
| GFR (mL/min/1.73 q) | PHA LTT | 2 | 0.47 | 0.02 |
| 7 | 0.44 | 0.04 | ||
| ConA LTT | 2 | 0.41 | 0.048 | |
| PHA IFN-γ ELISpot | 0 | 0.53 | 0.006 | |
| 2 | 0.66 | 0.001 | ||
| PWM IFN-γ ELISpot | 0 | 0.44 | 0.03 | |
| 1 | 0.46 | 0.02 | ||
| 2 | 0.60 | 0.002 | ||
| OKT3 IFN-γ ELISpot | 7 | 0.52 | 0.01 | |
| PHA IL-10 ELISpot | 0 | 0.56 | 0.005 | |
| 1 | 0.57 | 0.005 | ||
| 2 | 0.56 | 0.008 | ||
| 7 | 0.75 | < 0.0001 | ||
| 28 | 0.47 | 0.04 | ||
| ConA IL-10 ELISpot | 0 | 0.55 | 0.007 | |
| 1 | 0.44 | 0.04 | ||
| 2 | 0.47 | 0.03 | ||
| 7 | 0.74 | < 0.0001 | ||
| PWM IL-10 ELISpot | 0 | 0.54 | 0.007 | |
| 1 | 0.62 | 0.002 | ||
| 2 | 0.60 | 0.005 | ||
| 7 | 0.68 | 0.001 | ||
| Child–pugh score (no liver cirrhosis = 0, A = 1, B = 2, C = 3 | PPD IL-10 ELISpot | 0 | − 0.43 | 0.046 |
| 1 | − 0.54 | 0.01 | ||
| TET IL-10 ELISpot | 1 | − 0.56 | 0.008 | |
| CAN IL-10 ELISpot | 0 | − 0.45 | 0.04 | |
| 1 | − 0.46 | 0.04 | ||
| 2 | − 0.50 | 0.03 | ||
PHA phythohemagglutinin, LTT lymphocyte transformation test, Cum. antigen score Cumulative antigen score (sum of reactions toward antigens), IFN interferon, ConA concanavalin A, PWM pokeweed mitogen, TET tetanus toxoid, CAN Candida albicans, HSV-1 Herpes simplex virus type 1, GFR glomerular filtration rate, OKT3 anti-CD3 monoclonal antibody, PPD purified protein derivate (tuberculin), IL interleukin